Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Официальное название

Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations

Обзор

Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations. Eligible participants must have undergone curative-intent surgery and received guideline-appropriate perioperative systemic therapy, either neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy. Participants are randomized 1:1 to receive zongertinib or standard of care, which may consist of approved adjuvant immunotherapy or active surveillance, based on local practice guidelines. The main purpose of the study is to determine whether zongertinib can prolong disease-free survival compared to standard treatment. Safety and patient-reported outcomes are also assessed.

Подробное описание

This is a global, randomized, open-label, Phase 3 study designed to assess the efficacy and safety of zongertinib as adjuvant therapy in participants with completely resected Stage II-IIIB NSCLC and HER2 TKD-activating mutations.

Participants must have undergone complete resection and received perioperative systemic therapy consistent with current standards, including either neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy.

After completing surgery and required systemic treatment, eligible participants are randomized 1:1 to receive either Zongertinib taken orally once daily for up to 3 years, or standard treatment, which may include an approved adjuvant immunotherapy agent administered according to its label, or observation, depending on local clinical practice and patient status.

The primary objective is to evaluate whether zongertinib improves disease-free survival (DFS) compared with standard treatment. Secondary objectives include overall survival (OS), safety, tolerability, and patient-reported outcomes.

Вмешательства

• Препарат Zongertinib
  Zongertinib
• Препарат Pembrolizumab
  Pembrolizumab
• Препарат Atezolizumab
  Atezolizumab
• Препарат Durvalumab
  Durvalumab
• Препарат Nivolumab
  Nivolumab

Первичные конечные точки

• Disease-free survival (DFS) by investigator's assessment [Срок оценки: up to 8 years and 5 months]

Вторичные конечные точки (2)

• Key secondary endpoint: Overall survival (OS), defined as the time from randomization until death from any cause [Срок оценки: up to 8 years and 5 months]
• Occurrence of trial-related Adverse Events (AEs) ≥ Grade 3 from first treatment administration (or from randomization for patients in the observation arm) until the earliest of tumor recurrence or 3 years since treatment start [Срок оценки: up to 3 years]

Критерии участия

Критерии включения

• Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
• Patients must be ≥18 years old or over the legal age of consent in their country
• Male or female patients. Women of childbearing potential (WOCBP) must be ready and able to use dual highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information and in the study protocol
• HER2 mutation: Documented Tyrosine kinase domain (TKD) activating Human epidermal growth factor receptor 2 (HER2) mutations
• Histology and tumor sample: Histologically confirmed diagnosis of primary NSCLC
• An archival tumor tissue sample must be submitted to the central laboratory after inclusion of the patient to retrospectively confirm the HER2 status
• Staging: Pretherapeutic classification not exceeding Stage IIIB
• Performance status and organ function:

• Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
• Adequate organ function based on laboratory values Further inclusion criteria apply.

Критерии исключения

• Diagnosis of NSCLC with mixed histology/positive neuroendocrine markers (synaptophysin/CD56)
• Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to randomization
• Treatment with radiation therapy for primary NSCLC
• Co-occurring actionable mutation with approved targeted therapy (e.g. Epidermal growth factor receptor (EGFR) or Anaplastic lymphoma kinase (ALK))
• Any investigational drug within 5 half-lives of the compound or any of its related material, if known
• History or presence of

• Active or known pre-existing or history of non-infectious interstitial lung disease/pneumonitis
• Active infectious disease requiring systemic therapy
• Uncontrolled gastrointestinal disorders affecting drug intake/absorption
• Previous or concomitant malignancies within the last 3 years, except certain effectively treated cancers
• Significant and/or uncontrolled cardiovascular abnormalities, QT interval corrected for heart rate by Fridericia formula (QTcF) >470 msec, or ejection fraction <50% Further exclusion criteria apply.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

США · 28 центров

• ClinRé 001-022 (Premier Cancer Care and Infusion Center) — Fresno
• OPN Healthcare, Inc. — Glendale
• University of California Irvine — Irvine
• Sutter Health — Roseville
• University of California San Francisco — San Francisco
• Sarcoma Oncology Center — Santa Monica
• University of California Los Angeles — Santa Monica
• Northern California Kaiser Permanente — Vallejo
• … и ещё 20 центров

Китай · 28 центров

• China-Japan Friendship Hospital — Пекин
• Beijing Chest Hospital, Capital Medical University — Пекин
• The First Hospital of Jilin University — Changchun
• Xiangya Hospital, Central South University — Чанша
• Hunan Province Tumor Hospital — Чанша
• Sichuan Cancer Hospital — Чэнду
• West China Hospital, Sichuan University — Чэнду
• The First Affiliated Hospital,Sun Yat-sen University — Гуанчжоу
• … и ещё 20 центров

Япония · 25 центров

Список центров уточняется — проверьте первичный протокол.

Испания · 15 центров

Список центров уточняется — проверьте первичный протокол.

Германия · 9 центров

Список центров уточняется — проверьте первичный протокол.

Франция · 8 центров

Список центров уточняется — проверьте первичный протокол.

Италия · 8 центров

Список центров уточняется — проверьте первичный протокол.

South Korea · 8 центров

Список центров уточняется — проверьте первичный протокол.

Бразилия · 7 центров

• Hospital de Amor — Barretos
• NewData Clinical Research - Maceió — Maceió
• Centro de Pesquisa Oncology Natal — Natal
• Centro Gaúcho Integrado de Oncologia, Hematologia, Ensino e Pesquisa — Porto Alegre
• CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia — Santo André
• ICESP - Instituto do Cancer do Estado de Sao Paulo — São Paulo
• A.C. Camargo — São Paulo

Тайвань · 6 центров

Список центров уточняется — проверьте первичный протокол.

Великобритания · 6 центров

Список центров уточняется — проверьте первичный протокол.

Аргентина · 5 центров

• Centro de Investigaciones Médicas y Desarrollo LC S.R.L. (LC Investigación) — CABA
• Hospital Britanico de Buenos Aires — CABA
• Centro Oncologico Korben — CABA
• Clinica Adventista Belgrano — CABA
• Instituto Medico Especializado Alexander Fleming — Capital Federal

Австралия · 5 центров

• Royal North Shore Hospital — Sydney
• Princess Alexandra Hospital — Woolloongabba
• Flinders Medical Centre — Bedford Park
• Austin Health — Heidelberg
• St John of God Subiaco Hospital — Subiaco

Израиль · 5 центров

Список центров уточняется — проверьте первичный протокол.

Мексика · 5 центров

Список центров уточняется — проверьте первичный протокол.

Гонконг · 4 центра

Список центров уточняется — проверьте первичный протокол.

Португалия · 4 центра

Список центров уточняется — проверьте первичный протокол.

Румыния · 4 центра

Список центров уточняется — проверьте первичный протокол.

Бельгия · 3 центра

• Edegem - UNIV UZ Antwerpen — Edegem
• UZ Leuven — Leuven
• Centre Hospitalier Universitaire de Liège — Liège

Греция · 3 центра

Список центров уточняется — проверьте первичный протокол.

Австрия · 2 центра

• Medical University of Innsbruck — Innsbruck
• Clinic Floridsdorf — Vienna

Канада · 2 центра

• Cross Cancer Institute (University of Alberta) — Edmonton
• Princess Margaret Cancer Centre — Toronto

Чили · 2 центра

• Centro de Estudios Clinicos SAGA — Providencia
• Bradford Hill- Centro de Investigación Clínica — Recoleta

Швеция · 2 центра

Список центров уточняется — проверьте первичный протокол.

Turkey (Türkiye) · 2 центра

Список центров уточняется — проверьте первичный протокол.

Дания · 1 центр

Список центров уточняется — проверьте первичный протокол.

Нидерланды · 1 центр

Список центров уточняется — проверьте первичный протокол.

Сингапур · 1 центр

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07195695 · 1479-0032 · U1111-1320-6149 · 2025-521284-12-00

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗